$ATOS
ATOSSA THERAPEUTICS, INC.

2023 Q3 Form 10-Q Financial Statement

#000143774923023426 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.000M $4.088M
YoY Change -1.48% 29.29%
% of Gross Profit
Research & Development $4.467M $3.705M
YoY Change -13.43% 7.92%
% of Gross Profit
Depreciation & Amortization $0.00 $3.000K
YoY Change -100.0% 50.0%
% of Gross Profit
Operating Expenses $7.468M $7.793M
YoY Change -8.98% 18.17%
Operating Profit -$7.468M -$7.793M
YoY Change -8.98% 18.17%
Interest Expense $1.270M $983.0K
YoY Change -1256.47%
% of Operating Profit
Other Income/Expense, Net -$35.00K -$30.00K
YoY Change -118.04% -61.04%
Pretax Income -$6.229M -$9.830M
YoY Change -22.24% 47.33%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.229M -$9.830M
YoY Change -22.24% 47.33%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 -$0.08
Diluted Earnings Per Share -$0.05 -$0.08
COMMON SHARES
Basic Shares Outstanding 125.8M 126.6M
Diluted Shares Outstanding 125.8M 126.6M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.00M $99.39M
YoY Change -19.91% -20.83%
Cash & Equivalents $94.03M $99.39M
Short-Term Investments
Other Short-Term Assets $7.000K $7.000K
YoY Change -96.52% -99.55%
Inventory
Prepaid Expenses $3.472M $5.759M
Receivables
Other Receivables
Total Short-Term Assets $97.65M $106.0M
YoY Change -20.87% -20.55%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.700M $1.710M
YoY Change -37.04%
Other Assets $2.337M $642.0K
YoY Change 271.54% 2.39%
Total Long-Term Assets $4.047M $2.352M
YoY Change 21.57% 275.12%
TOTAL ASSETS
Total Short-Term Assets $97.65M $106.0M
Total Long-Term Assets $4.047M $2.352M
Total Assets $101.7M $108.4M
YoY Change -19.75% -19.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $718.0K $1.174M
YoY Change -56.56% -42.79%
Accrued Expenses $1.261M $803.0K
YoY Change 977.78% -3.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.444M $3.478M
YoY Change 20.08% -8.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.444M $3.478M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.444M $3.478M
YoY Change 20.08% -8.28%
SHAREHOLDERS EQUITY
Retained Earnings -$178.5M -$172.3M
YoY Change 20.06% 22.47%
Common Stock $277.7M $276.8M
YoY Change 2.08% 2.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $98.25M $104.9M
YoY Change
Total Liabilities & Shareholders Equity $101.7M $108.4M
YoY Change -19.75% -19.17%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$6.229M -$9.830M
YoY Change -22.24% 47.33%
Depreciation, Depletion And Amortization $0.00 $3.000K
YoY Change -100.0% 50.0%
Cash From Operating Activities -$3.880M -$4.465M
YoY Change -28.28% -24.95%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $13.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$13.00K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.480M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -3.880M -4.465M
Cash From Investing Activities 0.000 -13.00K
Cash From Financing Activities -1.480M 0.000
Net Change In Cash -5.360M -4.478M
YoY Change -33.96% -24.73%
FREE CASH FLOW
Cash From Operating Activities -$3.880M -$4.465M
Capital Expenditures $0.00 $13.00K
Free Cash Flow -$3.880M -$4.478M
YoY Change -28.2% -24.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126505000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126505000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126624000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126624000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
119000
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
CY2022Q2 atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
CY2023Q2 atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35610
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4753208
dei Entity Address Address Line1
EntityAddressAddressLine1
107 Spring Street
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98104
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei City Area Code
CityAreaCode
206
dei Local Phone Number
LocalPhoneNumber
588-0256
dei Security12b Title
Security12bTitle
Common Stock, $0.18 par value
dei Trading Symbol
TradingSymbol
ATOS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
125785200
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99390000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110890000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5759000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4031000 usd
CY2023Q2 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
737000 usd
CY2022Q4 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
743000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
7000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2423000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
106003000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
118197000 usd
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
1710000 usd
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
4700000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
642000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
635000 usd
CY2023Q2 us-gaap Assets
Assets
108355000 usd
CY2022Q4 us-gaap Assets
Assets
123532000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1174000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2965000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
803000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1059000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1455000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1525000 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
46000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
19000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3478000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5568000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
3478000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
5568000 usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
22792000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
22792000 usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
253960000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
250784000 usd
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
152000 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
-0 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172305000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156194000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
104877000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117964000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108355000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123532000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3705000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3433000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7213000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4937000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4088000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3162000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7678000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6411000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
7793000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
6595000 usd
us-gaap Operating Expenses
OperatingExpenses
14891000 usd
us-gaap Operating Expenses
OperatingExpenses
11348000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7793000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6595000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14891000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11348000 usd
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
2990000 usd
CY2022Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
-0 usd
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
2990000 usd
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
-0 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
983000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
11000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1833000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
13000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-88000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-122000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9830000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6672000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16111000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11457000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9830000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6672000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16111000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11457000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126623000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126623000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
138136000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1806000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4785000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
135157000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1771000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6672000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
130256000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117964000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1573000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
113256000 usd
CY2023Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
152000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1603000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9830000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
104877000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16111000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11457000 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3176000 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3577000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000 usd
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
2990000 usd
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-0 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-1000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1728000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2816000 usd
atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
-6000 usd
atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
-172000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2416000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
377000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-0 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
597000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1943000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
335000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-256000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
630000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-70000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-309000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
27000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
10000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11487000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10827000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11500000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10840000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
136487000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99500000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
125647000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99390000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
125537000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99500000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
125647000 usd
atos Unsettled Trades For Repurchase Of Common Stock
UnsettledTradesForRepurchaseOfCommonStock
152000 usd
atos Unsettled Trades For Repurchase Of Common Stock
UnsettledTradesForRepurchaseOfCommonStock
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>NOTE <em style="font: inherit;">1:</em> NATURE OF OPERATIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt; text-indent: 54pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Atossa Therapeutics, Inc. (the Company) was incorporated on <em style="font: inherit;"> April 30, 2009, </em>in the State of Delaware to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is focused on developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and other breast conditions. The Company's fiscal year ends on <em style="font: inherit;"> December 31.</em></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"> </p>
us-gaap Net Income Loss
NetIncomeLoss
-16111000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11487000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99390000 usd
CY2023Q2 atos Working Capital Deficit
WorkingCapitalDeficit
102525000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
21000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
803000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1059000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"><b><i>Reclassification </i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;">Interest income has been reclassified from prior period amounts to conform to the current year presentation.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"> </p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"><i><b>Estimates</b></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:54pt;"> </p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
2990000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21515000
us-gaap Operating Lease Expense
OperatingLeaseExpense
8000 usd
CY2023Q2 atos Research And Development Current
ResearchAndDevelopmentCurrent
4918000 usd
CY2022Q4 atos Research And Development Current
ResearchAndDevelopmentCurrent
3480000 usd
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
509000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
387000 usd
CY2023Q2 atos Professional Services Current
ProfessionalServicesCurrent
191000 usd
CY2022Q4 atos Professional Services Current
ProfessionalServicesCurrent
130000 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
141000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
34000 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5759000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4031000 usd
CY2023Q2 atos Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
559000 usd
CY2022Q4 atos Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1038000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
244000 usd
CY2023Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
507000 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1060000 usd
CY2023Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
232000 usd
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
224000 usd
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
716000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
241000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1455000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1525000 usd
CY2023Q2 atos Number Of Shares Authorized To Issue
NumberOfSharesAuthorizedToIssue
185000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 atos Stockholder Rights Agreement Number Of Preferred Stock Right Distributed For Each Share Of Common Stock
StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock
1
CY2014Q2 atos Stockholder Rights Agreement Acquiring Person Percentage Of Ownership
StockholderRightsAgreementAcquiringPersonPercentageOfOwnership
0.15 pure
CY2014Q2 atos Stockholder Rights Agreement Acquiring Person Percentage Of Ownership
StockholderRightsAgreementAcquiringPersonPercentageOfOwnership
0.15 pure
CY2014Q2 atos Stockholder Rights Agreement Acquiring Person Additional Percentage Of Ownership
StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership
0.020 pure
CY2014Q2 atos Stockholder Rights Agreement Initial Exercise Price Of Each Right
StockholderRightsAgreementInitialExercisePriceOfEachRight
15.00
CY2014Q2 atos Stockholder Rights Agreement Share Price
StockholderRightsAgreementSharePrice
30.00
CY2023Q2 atos Consummate A Business Combination Percentage Of Acquired Outstanding Shares
ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares
0.50 pure
CY2023Q2 atos Consummate A Business Combination Percentage Of Aggregate Ordinary Voting Power
ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower
0.50 pure
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21515000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39508000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35511000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37974000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34526000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
99208000 usd
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
110647000 usd
CY2023Q1 atos Lessee Operating Lease Monthly Rent Payments
LesseeOperatingLeaseMonthlyRentPayments
2000 usd
CY2023Q2 atos Lessee Operating Lease Monthly Rent Payments
LesseeOperatingLeaseMonthlyRentPayments
3000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
3000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
7000 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
2000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1603000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1771000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3176000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3577000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13906000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6691000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.82
atos Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
27000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
419000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
870.40
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20174000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.68
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M13D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3252000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
12823000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
20174000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.68
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M13D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3252000 usd
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
7351000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06 pure
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06 pure
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
50000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
106000 usd
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
36000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
68000 usd

Files In Submission

Name View Source Status
atos-20230630_pre.xml Edgar Link unprocessable
0001437749-23-023426-index-headers.html Edgar Link pending
0001437749-23-023426-index.html Edgar Link pending
0001437749-23-023426.txt Edgar Link pending
0001437749-23-023426-xbrl.zip Edgar Link pending
atos-20230630.xsd Edgar Link pending
atos20230630_10q.htm Edgar Link pending
ex_524818.htm Edgar Link pending
ex_524819.htm Edgar Link pending
ex_524820.htm Edgar Link pending
ex_524821.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
atos-20230630_cal.xml Edgar Link unprocessable
atos-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atos-20230630_def.xml Edgar Link unprocessable
atos20230630_10q_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending